Imperial College London


Faculty of MedicineDepartment of Immunology and Inflammation

Professor of Haemato-oncology



+44 (0)20 3313 3237j.apperley




Miss Mandy Sale +44 (0)20 3313 4017




4N3CHammersmith HospitalHammersmith Campus






Bencomo-Alvarez AE, Rubio AJ, Olivas IM, et al., 2021, Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B, Oncogene, ISSN:0950-9232

Hochhaus A, Boquimpani C, Rea D, et al., 2021, Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With >= 2 Tyrosine Kinase Inhibitors, Clinical Advances in Hematology & Oncology, Vol:19, ISSN:1543-0790, Pages:15-16

Garderet L, Sbianchi G, Iacobelli S, et al., 2021, Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT, European Journal of Haematology, ISSN:0902-4441

Clark RE, Apperley JF, Copland M, et al., 2021, Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression, Blood Advances, Vol:5, ISSN:2473-9529, Pages:1102-1109

Abruzzese E, Mauro M, Apperley J, et al., 2021, Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations, Therapeutic Advances in Hematology, Vol:11, ISSN:2040-6207, Pages:1-13

More Publications